MEFLOQUINE ( DrugBank: Mefloquine )
2 diseases
| 告示番号 | 疾患名（ページ内リンク） | 臨床試験数 |
|---|---|---|
| 25 | 進行性多巣性白質脳症 | 7 |
| 46 | 悪性関節リウマチ | 1 |
25. 進行性多巣性白質脳症
臨床試験数 : 26 / 薬物数 : 35 - (DrugBank : 22) / 標的遺伝子数 : 8 - 標的パスウェイ数 : 37
Showing 1 to 7 of 7 diseases
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | JPRN-UMIN000022151 | 2016/04/30 | 30/04/2016 | The efficacy and safety of mefloquine in patients with progressive multifocal leukoencephalopathy | The efficacy and safety of mefloquine in patients with progressive multifocal leukoencephalopathy - The efficacy and safety of mefloquine in patients with progressive multifocal leukoencephalopathy The efficacy and safety of mefloquinein patients with progressive multifocal leukoencephalopathy - T ... | The efficacy and safety of mefloquine in patients with progressive multifocal leukoencephalopathy | mefloquine is to be taken orally 275mg for 3days then 275mg weekly for 6 manths | Department of Neurology, Shimane University Hospital | NULL | Complete: follow-up complete | 20years-old | Not applicable | Male and Female | 5 | Not selected | Japan |
| 2 | JPRN-UMIN000023752 | 2016/04/14 | 24/08/2016 | Medication with mefloquine hydrochloride for progressive multifocal leukoencephalopathy (PML) out of the application range of insurance Medication with mefloquinehydrochloride for progressive multifocal leukoencephalopathy (PML) out of ... | Medication with mefloquine hydrochloride for progressive multifocal leukoencephalopathy (PML) out of the application range of insurance - Medication with mefloquine hydrochloride for progressive multifocal leukoencephalopathy (PML) out of the application range of insurance Medication with mefloquinehydrochloride for progressive multifocal leukoencephalopathy (PML) out of ... | progressive multifocal leukoencephalopathy | Oral mefloquine hydrochloride 275mg once a day at first 3 days. Since second week, 275mg in each week oral intake until 6 months Oral mefloquinehydrochloride 275mg once a day at first 3 days. Since second week, 275mg in each week ... | Nagoya City University | NULL | Complete: follow-up complete | Not applicable | Not applicable | Male and Female | 1 | Not applicable | Japan |
| 3 | EUCTR2008-001314-24-IT (EUCTR) | 15/01/2009 | 19/03/2009 | A Randomized, Rater-Blinded Study to Explore the Effect of Mefloquine in Subjects with Progressive Multifocal Leukoencephalopathy (PML) - ND A Randomized, Rater-Blinded Study to Explore the Effect of Mefloquinein Subjects with Progressive Mu ... | A Randomized, Rater-Blinded Study to Explore the Effect of Mefloquine in Subjects with Progressive Multifocal Leukoencephalopathy (PML) - ND A Randomized, Rater-Blinded Study to Explore the Effect of Mefloquinein Subjects with Progressive Mu ... | Progressive Multifocal Leukoencephalopathy (PML) MedDRA version: 9.1;Level: LLT;Classification code 10036807;Term: Progressive multifocal leukoencephalopathy Progressive Multifocal Leukoencephalopathy (PML) MedDRA version: 9.1;Level: LLT;Classification code ... | Trade Name: Lariam INN or Proposed INN: Mefloquine | BIOGEN IDEC LTD | NULL | Not Recruiting | Female: yes Male: yes | 40 | United Kingdom;France;Spain;Italy | |||
| 4 | EUCTR2008-001314-24-GB (EUCTR) | 02/01/2009 | 28/05/2008 | A Randomized, Rater-Blinded Study to Explore the Effect of Mefloquine in Subjects with Progressive Multifocal Leukoencephalopathy (PML) A Randomized, Rater-Blinded Study to Explore the Effect of Mefloquinein Subjects with Progressive Mu ... | A Randomized, Rater-Blinded Study to Explore the Effect of Mefloquine in Subjects with Progressive Multifocal Leukoencephalopathy (PML) A Randomized, Rater-Blinded Study to Explore the Effect of Mefloquinein Subjects with Progressive Mu ... | Progressive Multifocal Leukoencephalopathy (PML) MedDRA version: 9.1;Level: LLT;Classification code 10036807;Term: Progressive multifocal leukoencephalopathy Progressive Multifocal Leukoencephalopathy (PML) MedDRA version: 9.1;Level: LLT;Classification code ... | Trade Name: Lariam Product Name: Mefloquine Product Code: 111JC101 INN or Proposed INN: MEFLOQUINE | Biogen Idec Ltd | NULL | Not Recruiting | Female: yes Male: yes | 60 | United Kingdom;France;Spain;Italy | |||
| 5 | NCT00746941 (ClinicalTrials.gov) | January 2009 | 3/9/2008 | Study to Explore the Effect of Mefloquine in Participants With Progressive Multifocal Leukoencephalopathy (PML) Study to Explore the Effect of Mefloquinein Participants With Progressive Multifocal Leukoencephalop ... | A Randomized, Rater-Blinded Study to Explore the Effect of Mefloquine in Subjects With Progressive Multifocal Leukoencephalopathy (PML) A Randomized, Rater-Blinded Study to Explore the Effect of Mefloquinein Subjects With Progressive Mu ... | Progressive Multifocal Leukoencephalopathy | Drug: mefloquine | Biogen | Elan Pharmaceuticals | Terminated | 18 Years | 75 Years | All | 37 | Phase 1/Phase 2 | United States;Brazil;Germany;Italy;Spain;Australia;France;Puerto Rico;United Kingdom |
| 6 | EUCTR2008-001314-24-ES (EUCTR) | 19/11/2008 | 11/07/2008 | A Randomized, Rater-Blinded Study to Explore the Effect of Mefloquine in Subjects with Progressive Multifocal Leukoencephalopathy (PML)Estudio aleatorizado con evaluador en condiciones de ciego para explorar el efecto de mefloquina en sujetos con leucoencefalopatía multifocal progresiva (LMP) A Randomized, Rater-Blinded Study to Explore the Effect of Mefloquinein Subjects with Progressive Mu ... | A Randomized, Rater-Blinded Study to Explore the Effect of Mefloquine in Subjects with Progressive Multifocal Leukoencephalopathy (PML)Estudio aleatorizado con evaluador en condiciones de ciego para explorar el efecto de mefloquina en sujetos con leucoencefalopatía multifocal progresiva (LMP) A Randomized, Rater-Blinded Study to Explore the Effect of Mefloquinein Subjects with Progressive Mu ... | Progressive Multifocal Leukoencephalopathy (PML)Leucoencefalopatía Multifocal Progresiva (LMP) MedDRA version: 9.1;Level: LLT;Classification code 10036807;Term: Progressive multifocal leukoencephalopathy Progressive Multifocal Leukoencephalopathy (PML)Leucoencefalopatía Multifocal Progresiva (LMP) MedDR ... | Trade Name: Lariam Product Name: Mefloquine Product Code: 111JC101 INN or Proposed INN: MEFLOQUINE | Biogen Idec Ltd | NULL | Not Recruiting | Female: yes Male: yes | 40 | Phase 2 | France;Spain;Italy;United Kingdom | ||
| 7 | EUCTR2008-001314-24-FR (EUCTR) | 22/10/2008 | 23/07/2008 | A Randomized, Rater-Blinded Study to Explore the Effect of Mefloquine in Subjects with Progressive Multifocal Leukoencephalopathy (PML) A Randomized, Rater-Blinded Study to Explore the Effect of Mefloquinein Subjects with Progressive Mu ... | A Randomized, Rater-Blinded Study to Explore the Effect of Mefloquine in Subjects with Progressive Multifocal Leukoencephalopathy (PML) A Randomized, Rater-Blinded Study to Explore the Effect of Mefloquinein Subjects with Progressive Mu ... | Progressive Multifocal Leukoencephalopathy (PML) MedDRA version: 9.1;Level: LLT;Classification code 10036807;Term: Progressive multifocal leukoencephalopathy Progressive Multifocal Leukoencephalopathy (PML) MedDRA version: 9.1;Level: LLT;Classification code ... | Trade Name: Lariam Product Name: Mefloquine Product Code: 111JC101 INN or Proposed INN: MEFLOQUINE | Biogen Idec Ltd | NULL | Not Recruiting | Female: yes Male: yes | 40 | Phase 2 | France;Spain;Italy;United Kingdom |
46. 悪性関節リウマチ
臨床試験数 : 4,356 / 薬物数 : 2,567 - (DrugBank : 415) / 標的遺伝子数 : 192 - 標的パスウェイ数 : 228
Showing 1 to 1 of 1 diseases
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | EUCTR2005-002421-31-DE (EUCTR) | 20/10/2005 | 03/11/2005 | A phase II randomised, double-blind, multicenter, placebo-controlled, dose-ranging, parallel group study to compare the efficacy, safety and tolerability of 3 strengths of AD 452 in adult subjects with active rheumatoid arthritis who are currently taking methotrexate. - Efficacy, safety and tolerability of AD 452 in patients wih RA A phase II randomised, double-blind, multicenter, placebo-controlled, dose-ranging, parallel group s ... | A phase II randomised, double-blind, multicenter, placebo-controlled, dose-ranging, parallel group study to compare the efficacy, safety and tolerability of 3 strengths of AD 452 in adult subjects with active rheumatoid arthritis who are currently taking methotrexate. - Efficacy, safety and tolerability of AD 452 in patients wih RA A phase II randomised, double-blind, multicenter, placebo-controlled, dose-ranging, parallel group s ... | The purpose of this clinical trial is to evaluate the clinical efficacy, safety and tolerability of three doses of AD 452 in comparison with placebo in the treatment of subjects with active rheumatoid arthritis. MedDRA version: 7.0;Level: PT;Classification code 10039073 The purpose of this clinical trial is to evaluate the clinical efficacy, safety and tolerability of ... | Product Name: AD 452 INN or Proposed INN: (+) isomer of racemic mefloquine Other descriptive name: (+)erythromefloquine Product Name: AD 452 INN or Proposed INN: (+) isomer of racemic mefloquine Other descriptive name: (+) erythromefloquine Product Name: AD 452 INN or Proposed INN: (+) isomer or racemic mefloquine Other descriptive name: (+) erythromefloquine Product Name: AD 452 INN or Proposed INN: (+) isomer of racemic mefloquine Other descriptive name: (+) ... | Arakis Ltd. | NULL | Not Recruiting | Female: yes Male: yes | 292 | Phase 2 | United Kingdom;Germany |